X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
The randomized, double-blind, placebo-controlled Phase 2 clinical trial is supported by funding from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health and will evaluate EMB-001 as a treatment option for patients with cocaine use disorder.
Lead Product(s): Metyrapone,Oxazepam
Therapeutic Area: Psychiatry/Psychology Product Name: EMB-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
